NASDAQ : EIKN
Eikon Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 5.31 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 287.62M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 287.62M |
| Enterprise Value | 8.66M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 54.17M |
| Shares Outstanding | 54.17M |
| Shares Change (YoY) | +831.80% |
| Shares Change (QoQ) | +60.66% |
| Owned by Insiders (%) | 6.26% |
| Owned by Institutions (%) | 51.71% |
| Float | 34.78M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.62 |
| P/TBV Ratio | 0.62 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 9.89 |
| Quick Ratio | 9.61 |
| Debt / Equity | 0.54 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -404.36 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -46.73% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$838,961 |
| Employee Count | 384 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 8.59 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 28.15 |
| Average Volume (20 Days) | 546,500 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 6.37M |
| Short Previous Month | 6.29M |
| Short % of Shares Out | 11.76% |
| Short % of Float | 18.32% |
| Short Ratio (days to cover) | 9.85 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -338.45M |
| Pretax Income | -322.16M |
| Net Income | -322.16M |
| EBITDA | -317.23M |
| EBIT | -338.45M |
| Earnings Per Share (EPS) | -$13.72 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 531.18M |
| Total Debt | 252.22M |
| Net Cash | 278.96M |
| Net Cash Per Share | $5.15 |
| Equity (Book Value) | 466.50M |
| Book Value Per Share | 8.62 |
| Working Capital | 491.68M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -256.02M |
| Capital Expenditures | -3.18M |
| Depreciation & Amortization | 21.22M |
| Net Borrowing | n/a |
| Free Cash Flow | -259.20M |
| FCF Per Share | -$4.79 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -831.80% |
| Shareholder Yield | n/a |
| Earnings Yield | -258.41% |
| FCF Yield | -90.12% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $24.33 |
| Price Target Difference | 358.19% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |